Athenex Inc ATNX:NASDAQ

Last Price$1.10Cboe Real-Time Last Sale as of 3:52PM ET 8/10/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change0.00(0.00%)
Bid (Size)$1.09 (1,000)
Ask (Size)$1.12 (400)
Day Low / High$1.06 - 1.15
Volume886.5 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/10/2022

 

Athenex Inc ( NASDAQ )

Price: $1.10
Change: 0.00 (0.00%)
Volume: 886.5 K
3:52PM ET 8/10/2022
 
 

RVL Pharmaceuticals PLC ( NASDAQ )

Price: $1.91
Change: +0.31 (19.37%)
Volume: 655.0 K
3:46PM ET 8/10/2022
 
 

TCR2 Therapeutics Inc ( NASDAQ )

Price: $3.51
Change: +0.13 (3.85%)
Volume: 247.2 K
3:50PM ET 8/10/2022
 
 

Citius Pharmaceuticals Inc ( NASDAQ )

Price: $1.07
Change: +0.12 (12.11%)
Volume: 1.2 M
3:50PM ET 8/10/2022
 
 

Verrica Pharmaceuticals Inc ( NASDAQ )

Price: $3.46
Change: +0.21 (6.46%)
Volume: 80.9 K
3:46PM ET 8/10/2022
 

Read more news Recent News

-- Earnings Flash (ATNX) ATHENEX Reports Q2 Revenue $31.5M
7:00AM ET 7/28/2022 MT Newswires

...

Sector Update: Health Care Stocks Edging Lower at Close
4:02PM ET 7/11/2022 MT Newswires

Health care stocks were narrowly lower this afternoon, with the NYSE Health Care Index sliding 0.2% while the SPDR Health Care Select Sector ETF (XLV) was...

Sector Update: Health Care Stocks Still Little Changed
1:31PM ET 7/11/2022 MT Newswires

Health care stocks were narrowly mixed this afternoon, with the NYSE Health Care Index rising less than 0.1% while the SPDR Health Care Select Sector ETF...

Athenex to Sell China API Manufacturing Units to TiHe Capital for $19 Million
10:03AM ET 7/11/2022 MT Newswires

Athenex (ATNX) said Monday it has struck a deal to sell its China units, which are mainly engaged in the making of active pharmaceutical ingredients, to...

Company Profile

Business DescriptionAthenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY. View company web site for more details
AddressConventus Building
Buffalo, New York 14203-1009
Phone+1.716.427.2950
Number of Employees582
Recent SEC Filing08/01/20224
Chairman & Chief Executive OfficerYiu Nam Lau
COO & President-Athenex Pharmaceutical DivisionJeff Yordon
Chief Financial OfficerJoe Annoni
Chief Scientific OfficerMichael Smolinski

Company Highlights

Price Open$1.10
Previous Close$1.10
52 Week Range$0.41 - 3.91
Market Capitalization$133.8 M
Shares Outstanding121.6 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.27
Beta vs. S&P 500N/A
Revenue$89.1 M
Net Profit Margin-161.21%
Return on Equity-302.04%

Analyst Ratings as of 07/14/2022

Buy
2
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset